Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Non-Segmental Vitiligo
NCT06327321Phase 2Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- May 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in Vitiligo (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoints: Proportion of patients achieving VITIL-IA 50 at 24 weeks and Rate of depigmentation at 24 weeks. Started May 2024; status: active, not recruiting.
02
Drugs
deucravacitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06327321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06327321.